Mitral Transcatheter Edge-to-Edge Repair in a Challenging Anatomy With Deeply Implanted Self-Expanding Valve and Severe Mitral Annular Calcification: A Case Report Authors: Muhammad Saad, Raviteja Guddeti, Nadia El-Hangouche, Santiago Garcia Published: 2026 ABSTRACT AbstractMitral transcatheter edge-to-edge repair (M-TEER) in the setting of prior transcatheter aortic valve replacement (TAVR) and severe mitral annular calcification (MAC) can pose procedural challenges. We describe the case of an 82-year-old woman with prior TAVR (29 mm EVOLUT FX+; Medtronic), P2 flail, and heavy circumferential MAC underwent M-TEER with the PASCAL Ace device (Edwards Lifesciences). This case illustrates that M-TEER can be performed safely and effectively in anatomies complicated by severe MAC and prior TAVR with careful preprocedural planning, intraprocedural imaging, and operator experience.Keywords: case report, mitral regurgitation, M-TEER Introduction Mitral regurgitation (MR) is the most common valvular heart disease in the United States1 and remains a major contributor to heart failure morbidity and mortality. Currently, 2 dedicated device systems are approved for mitral transcatheter edge-to-edge repair (M-TEER) in the United States: the MitraClip (Abbott) and the PASCAL (Edwards Lifesciences) systems. As experience with these devices has grown, M-TEER has been increasingly performed in patients with complex anatomies, including those with prior transcatheter aortic valve replacement (TAVR)2 and severe mitral annular calcification (MAC). These anatomical features can pose unique technical challenges related to transseptal puncture, leaflet grasping, and device positioning. We describe a case of successful M-TEER in a patient with severe MR, heavy circumferential MAC, and a deeply implanted EVOLUT valve, illustrating how thoughtful device selection and simple procedural maneuvers may overcome challenging anatomy. Case summary An 82-year-old woman with a history of TAVR with a self-expanding 29-mm EVOLUT FX+ valve (Medtronic) presented for evaluation of severe MR. Imaging demonstrated a highly eccentric jet of MR, which appeared to be degenerative in etiology, as evident by the P2 flail. Anatomy was complex due to severe MAC with a mean transmitral gradient of ∼5 mm Hg and an EVOLUT FX+ valve extending 3 mm below the noncoronary cusp. Given the patient’s advanced age, frailty, and extensive MAC, she was deemed to be at prohibitive surgical risk. The multidisciplinary heart team determined that transcatheter M-TEER offered the most appropriate therapeutic strategy. Considering the challenging anatomy, the PASCAL Ace device was selected for its compact, low-profile design, and enhanced ability to navigate a restricted mitral orifice. Procedural steps The procedure was performed under general anesthesia and transesophageal guidance. Right femoral vein was used for access, and an 8F sheath was placed through which a VersaCross radiofrequency transseptal platform (Boston Scientific) was advanced to superior vena cava over a 135-cm 0.032-inch guide wire. System was then withdrawn to fossa ovalis under TEE and fluoroscopy guidance. After confirming the orientation using bicaval and short axis views, a transseptal puncture was made at height of ∼4 to 5 cm in relationship to mitral annular plane using a 4-chamber view. The needle was advanced into left atrium, and the introducer was advanced over it. Finally, the sheath was advanced over the introducer. At this point, needle and introducer were removed and the VersaCross wire (Boston Scientific) was advanced to the LA to serve as a rail for catheter exchanges. Steerable guide catheter and introducer were advanced into LA, and wire and introducer were both removed. After introducing into the guiding catheter, the PASCAL Ace device was closed and steered toward the mitral valve plane using the flex wheel on the steerable catheter. Device was aligned in A2-P2 using the midcommissural and long-axis views along with 3D reconstructions. Subsequently, we oriented the device by clocking the implant catheter (12-6 orientation). At this point, there was unwanted interaction of the PASCAL Ace device with the frame of EVOLUT valve anteriorly and MAC posteriorly (Figure 1). To avoid this interaction, the implant was inverted and elongated to form a diamond-grasp (Figure 2) (Supplemental Videos S1 and S2). It was advanced into LV in a posterior trajectory which avoided the interaction of the device with the surrounding structures (Figure 3). Anterior and posterior leaflets were now resting on the device paddles (Figure 4). In this position, the clasps were deployed sequentially (posterior first) and more than 6 mm of leaflets were captured without interaction with MAC and EVOLUT frame. Intraprocedural transesophageal echocardiogram and fluoroscopy showing interaction of device with surrounding structures. (Left and middle) PASCAL Ace device (P) is seen in the middle interacting with EVOLUT frame (E) anteriorly and thick shelf of MAC (M) posteriorly. (Right) Fluoroscopic view at the time of interaction between PASCAL device (white arrow) and EVOLUT frame (red arrow). LA, left atrium; LV, left ventricle; MAC, mitral annular calcification. Echocardiographic visualization of Diamond grasp to navigate through the complex anatomy. The left image demonstrates the posterior delivery system trajectory. The right image shows a partially deployed PASCAL Ace device in diamond grasp configuration (P), as visualized during the procedure. (Left) CTA short-axis MIP demonstrating a circumferential extent of MAC spanning 245°. (Middle) Intraprocedural TEE in bicommissural view. (Right) Biplane grasping view at the level of the PASCAL device. The yellow arrow indicates the anterior leaflet hinge point distal to the EVOLUT inflow; the star denotes acoustic shadowing from severe MAC. Blue and orange lines represent the anterior (10.8 mm) and posterior (11.0 mm) leaflets lying appropriately on the PASCAL device arms. Blue arrowheads indicate the device arms in grasping-ready position. CTA, computed tomography angiography; MAC, mitral annular calcification; MIP, maximal intensity projection; TEE, transesophageal echocardiogram. Echocardiogram showing PASCAL device in left ventricle ready to be deployed. PASCAL Ace device is in LV in leaflet-capture-ready position with good landing of anterior (highlighted yellow) and posterior leaflet (highlighted green) on the paddles. LV, left ventricle. At 1-month follow-up, transthoracic echocardiography demonstrated mild MR and a mean transmitral gradient of 4 mm Hg. Discussion M-TEER in the setting of complex anatomy—particularly in the presence of severe MAC and a prior TAVR—can be performed safely and effectively with careful and meticulous procedural planning. In the setting of severe MAC, the risk of inducing iatrogenic mitral stenosis is substantial. Careful device orientation and continuous intraprocedural assessment of transmitral gradients are critical prior to final deployment to minimize this risk. Additionally, because the PASCAL system is relatively new, operators may have limited experience with its full range of steering and maneuvering capabilities, which may further increase procedural complexity. In anatomies where device–structure interaction poses significant challenges, the elongated profile3 and steerability of the PASCAL Ace implant may facilitate navigation through restricted orifices; however, several other factors play a role in the safety and outcomes of the procedure. Ultimately, thoughtful device and patient selection, operator experience, and patient-specific procedural planning are among the key determinants of procedural success in M-TEER.4,5 Conclusion M-TEER can be performed safely and effectively in anatomies complicated by severe MAC and prior TAVR when guided by careful preprocedural planning, intraprocedural imaging and monitoring, and operator and institutional experience. Device selection is important and can be influenced by multiple factors including availability, operator experience, and substrate anatomy. Studies are needed to compare the outcomes associated with different M-TEER devices in complex anatomies. CRediT authorship contribution statement Muhammad Saad: Writing – review & editing, Writing – original draft, Data curation. Raviteja Guddeti: Writing – review & editing, Data curation. Nadia El-Hangouche: Writing – review & editing, Supervision, Data curation. Santiago Garcia: Writing – review & editing, Supervision, Conceptualization. Declaration of competing interest The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Acknowledgments Funding sources This work was not supported by funding agencies in the public, commercial or not-for-profit sectors. Ethics statement and patient consent This study was exempt from institutional review board (IRB) review as it involved the retrospective reporting of a single deidentified patient case and did not meet the regulatory definition of human subject research. Informed consent was obtained in accordance with local guidelines. Footnotes To access the supplementary material accompanying this article, visit the online version of the Journal of the Society for Cardiovascular Angiography & Interventions at 10.1016/j.jscai.2026.105571. Supplementary material Supplementary Video S1 Supplementary Video S2 References Associated Data Supplementary Materials Supplementary Video S1 Supplementary Video S2